Literature DB >> 12432920

Arachidonate 5-lipoxygenase.

Olof Rådmark1.   

Abstract

In this article, it has been attempted to review data primarily on the activation of human 5-lipoxygenase, in vitro and in the cell. First, structural properties and enzyme activities are described. This is followed by the activating factors: Ca2+, membranes, ATP, and lipid hydroperoxide. Also, studies on phosphorylation of 5-lipoxygenase, interaction with other proteins, and the intracellullar mobility of 5-lipoxygenase, are reviewed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12432920     DOI: 10.1016/s0090-6980(02)00032-1

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  23 in total

1.  Very long-chain fatty acid accumulation causes lipotoxic response via 5-lipoxygenase in cerebral adrenoleukodystrophy.

Authors:  Mushfiquddin Khan; Jaspreet Singh; Anne G Gilg; Takuhiro Uto; Inderjit Singh
Journal:  J Lipid Res       Date:  2010-02-20       Impact factor: 5.922

2.  NMR structure of human coactosin-like protein.

Authors:  Edvards Liepinsh; Marija Rakonjac; Vincent Boissonneault; Patrick Provost; Bengt Samuelsson; Olof Rådmark; Gottfried Otting
Journal:  J Biomol NMR       Date:  2004-11       Impact factor: 2.835

Review 3.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

Review 4.  Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers.

Authors:  Charles N Serhan; Makoto Arita; Song Hong; Katherine Gotlinger
Journal:  Lipids       Date:  2004-11       Impact factor: 1.880

Review 5.  Lipid peroxidation in cell death.

Authors:  Michael M Gaschler; Brent R Stockwell
Journal:  Biochem Biophys Res Commun       Date:  2017-02-03       Impact factor: 3.575

6.  Association of Sp1 tandem repeat polymorphism of ALOX5 with coronary artery disease in Indian subjects.

Authors:  Seema P Todur; Tester F Ashavaid
Journal:  Clin Transl Sci       Date:  2012-03-06       Impact factor: 4.689

7.  Human lipoxygenase pathway gene variation and association with markers of subclinical atherosclerosis in the diabetes heart study.

Authors:  Kathryn P Burdon; Megan E Rudock; Allison B Lehtinen; Carl D Langefeld; Donald W Bowden; Thomas C Register; Yongmei Liu; Barry I Freedman; J Jeffrey Carr; Catherine C Hedrick; Stephen S Rich
Journal:  Mediators Inflamm       Date:  2010-05-31       Impact factor: 4.711

8.  A covalent linker allows for membrane targeting of an oxylipin biosynthetic complex.

Authors:  Nathaniel C Gilbert; Marc Niebuhr; Hiro Tsuruta; Tee Bordelon; Oswin Ridderbusch; Adam Dassey; Alan R Brash; Sue G Bartlett; Marcia E Newcomer
Journal:  Biochemistry       Date:  2008-09-12       Impact factor: 3.162

9.  Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610.

Authors:  Lutz Fischer; Dieter Steinhilber; Oliver Werz
Journal:  Br J Pharmacol       Date:  2004-06-14       Impact factor: 8.739

10.  Functional analysis of 5-lipoxygenase promoter repeat variants.

Authors:  Susanna Vikman; Romulo M Brena; Patrice Armstrong; Jaana Hartiala; Charles B Stephensen; Hooman Allayee
Journal:  Hum Mol Genet       Date:  2009-08-28       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.